Pharminox promotes Dr Marc Hummersone
pharmafile | August 12, 2010 | Appointment | Research and Development | Pharminox, appointment, research and development
Nottingham, UK-based cancer drug discovery and development company Pharminox has appointed Dr Marc Hummersone as research director.
Marc first joined the company from KuDOS Pharmaceuticals in April 2008 as head of chemistry, and in his new role , will take on full responsibility for discovery research operations and strategy within Pharminox.
Meanwhile, Professor Malcolm Stevens is standing down from the board and as chief scientific officer (CSO) and will take up the honorary position of CSO Emeritus
Peter Worrall, chief executive of Pharminox said: “Marc’s appointment recognises the exceptional contribution that he has made in the two years since he came to Pharminox, both in building a high calibre discovery research team and also in refining the Company’s discovery activities to focus on targeted DNA damage and inhibition of DNA repair.
“I would also like to take this opportunity to thank Malcolm Stevens for the huge contribution he has made to the development of Pharminox over the last six years. I am very pleased that Malcolm intends to retain close ties with the Company in his new role as CSO Emeritus, and that we will continue to benefit from his valuable insights and enormous experience in cancer drug discovery.”
Related Content

PlasmidFactory founder Dr. Martin Schleef honoured with the NRW Innovation Award 2025
The founder and long-standing CEO of PlasmidFactory, Dr. Martin Schleef, was honoured in Düsseldorf with …

AAX Biotech announces collaboration for cardiovascular antibody therapy
Swedish biotech firm AAX Biotech has entered a new collaboration focused on the development of …

Research finds tablet effective in slowing progression of Alzheimer’s disease over 18 months
TauRx Pharmaceutics reports that hydromethylthionine mesylate (HMTM) could be an oral treatment for slowing the …






